J
Journey Medical Corp (DERM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
$3.70
-0.63 (-14.55%)
Market Cap: $122.24M
Last updated: Nov 17, 2026 at 11:04 AM ET
Journey Medical Corp (DERM) Valuation Multiples
Journey Medical (DERM) trades at 1.5x sales and 3.2x book value. Its P/S of 1.5x is above its 5-year median of 1.3x. Its forward P/E is 17.3x.
Current Multiples
Its enterprise value is 41.2x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 17.3x |
| Price to sales | 1.5x |
| Price to book | 3.2x |
| EV/EBITDA | 41.2x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.5x | 1.3x | N/A |
| P/B | 3.2x | 5.2x | N/A |
Valuation History
Over the 5 year ends shown, its P/S ranged from 0.5x in 2022 to 3.0x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $7.71 | 3.0x | 5.9x |
| 2024 | $3.91 | 1.4x | 4.3x |
| 2023 | $5.76 | 1.3x | 5.5x |
| 2022 | $1.92 | 0.5x | 2.0x |
| 2021 | $5.38 | 0.9x | 1.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DERM
What is DERM's forward P/E ratio?
Journey Medical has a forward P/E ratio of 17.3x.
Is DERM stock overvalued?
GNG's valuation label for DERM is Undervalued.
What is DERM's price to sales ratio?
Journey Medical has a price to sales ratio of 1.5x.
DERM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors